BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 17341531)

  • 1. Retisert: is the new advance in treatment of uveitis a good one?
    Mohammad DA; Sweet BV; Elner SG
    Ann Pharmacother; 2007 Mar; 41(3):449-54. PubMed ID: 17341531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study.
    Jaffe GJ; Martin D; Callanan D; Pearson PA; Levy B; Comstock T;
    Ophthalmology; 2006 Jun; 113(6):1020-7. PubMed ID: 16690128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis.
    Arcinue CA; Cerón OM; Foster CS
    J Ocul Pharmacol Ther; 2013 Jun; 29(5):501-7. PubMed ID: 23297752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis.
    Jaffe GJ; McCallum RM; Branchaud B; Skalak C; Butuner Z; Ashton P
    Ophthalmology; 2005 Jul; 112(7):1192-8. PubMed ID: 15921758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reimplantation of a fluocinolone acetonide sustained drug delivery implant for chronic uveitis.
    Jaffe GJ
    Am J Ophthalmol; 2008 Apr; 145(4):667-675. PubMed ID: 18226800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined fluocinolone acetonide intraocular delivery system insertion, phacoemulsification, and intraocular lens implantation for severe uveitis.
    Chieh JJ; Carlson AN; Jaffe GJ
    Am J Ophthalmol; 2008 Oct; 146(4):589-594. PubMed ID: 18639220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of intractable posterior uveitis in pediatric patients with the fluocinolone acetonide intravitreal implant (Retisert).
    Patel CC; Mandava N; Oliver SC; Braverman R; Quiroz-Mercado H; Olson JL
    Retina; 2012 Mar; 32(3):537-42. PubMed ID: 21963487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of fluocinolone acetonide implant (Retisert) reimplantation for chronic noninfectious posterior uveitis.
    Taban M; Lowder CY; Kaiser PK
    Retina; 2008 Oct; 28(9):1280-8. PubMed ID: 18628725
    [No Abstract]   [Full Text] [Related]  

  • 9. Combined fluocinolone acetonide intravitreal insertion and glaucoma drainage device placement for chronic uveitis and glaucoma.
    Malone PE; Herndon LW; Muir KW; Jaffe GJ
    Am J Ophthalmol; 2010 May; 149(5):800-6.e1. PubMed ID: 20189158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis.
    Pavesio C; Zierhut M; Bairi K; Comstock TL; Usner DW;
    Ophthalmology; 2010 Mar; 117(3):567-75, 575.e1. PubMed ID: 20079922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dexamethasone for ocular inflammation.
    Saraiya NV; Goldstein DA
    Expert Opin Pharmacother; 2011 May; 12(7):1127-31. PubMed ID: 21457057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluocinolone acetonide ophthalmic--Bausch & Lomb: fluocinolone acetonide Envision TD implant.
    Drugs R D; 2005; 6(2):116-9. PubMed ID: 15777105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retisert (Bausch & Lomb/Control Delivery Systems).
    Lim LL; Smith JR; Rosenbaum JT
    Curr Opin Investig Drugs; 2005 Nov; 6(11):1159-67. PubMed ID: 16312138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytomegalovirus retinitis after fluocinolone acetonide (Retisert) implant.
    Ufret-Vincenty RL; Singh RP; Lowder CY; Kaiser PK
    Am J Ophthalmol; 2007 Feb; 143(2):334-5. PubMed ID: 17258523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New developments in corticosteroid therapy for uveitis.
    Taylor SR; Isa H; Joshi L; Lightman S
    Ophthalmologica; 2010; 224 Suppl 1():46-53. PubMed ID: 20714181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of fluocinolone acetonide sustained release implant (Retisert) dissociation during implant removal and exchange surgery.
    Nicholson BP; Singh RP; Sears JE; Lowder CY; Kaiser PK
    Am J Ophthalmol; 2012 Dec; 154(6):969-973.e1. PubMed ID: 22981365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Late spontaneous dissociation of a fluocinolone acetonide implant (Retisert).
    Rofagha S; Prechanond T; Stewart JM
    Ocul Immunol Inflamm; 2013; 21(1):77-8. PubMed ID: 23323586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus endotheliitis after fluocinolone acetonide (Retisert) implant in a patient with Behçet uveitis.
    Park UC; Kim SJ; Yu HG
    Ocul Immunol Inflamm; 2011 Aug; 19(4):282-3. PubMed ID: 21770807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Long-Lasting Intravitreous Fluocinolone Acetonide Implant vs Systemic Anti-inflammatory Therapy and Visual Acuity at 7 Years Among Patients With Intermediate, Posterior, or Panuveitis.
    ; Kempen JH; Altaweel MM; Holbrook JT; Sugar EA; Thorne JE; Jabs DA
    JAMA; 2017 May; 317(19):1993-2005. PubMed ID: 28477440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dissociations of the Fluocinolone Acetonide Implant: The Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study.
    Holbrook JT; Sugar EA; Burke AE; Vitale AT; Thorne JE; Davis JL; Jabs DA;
    Am J Ophthalmol; 2016 Apr; 164():29-36. PubMed ID: 26748056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.